[1]邸金娜,刘敬禹,张 莉.基于网络药理及分子对接技术对人参治疗非小细胞肺癌作用机制研究[J].陕西医学杂志,2021,50(6):669-672,677.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.007]
　DI Jinna,LIU Jingyu,ZHANG Li.Mechanism of ginseng in NSCLC treatment based on network pharmacology and molecular docking technology[J].,2021,50(6):669-672,677.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.007]
点击复制

基于网络药理及分子对接技术对人参治疗非小细胞肺癌作用机制研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年6期
页码:
669-672,677
栏目:
基础研究
出版日期:
2021-06-05

文章信息/Info

Title:
Mechanism of ginseng in NSCLC treatment based on network pharmacology and molecular docking technology
作者:
邸金娜; 刘敬禹; 张 莉
(锦州医科大学附属第三医院呼吸内科,辽宁 锦州 121001)
Author(s):
DI Jinna; LIU Jingyu; ZHANG Li
(Department of Respiratory Medicine,the Third Affiliated Hospital of Jinzhou Medical University,Jinzhou 121001,China)
关键词:
人参;  非小细胞肺癌;  网络药理学;  分子对接技术;  核心靶点;  作用机制
Keywords:
Ginseng;  Non-small cell lung cancer;  Network pharmacology;  Molecular docking;  Core target;  Mechanism of action
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2021.06.007
文献标志码:
A
摘要:
目的:基于网络药理及分子对接技术预测人参治疗非小细胞肺癌(NSCLC)的潜在靶点,并探讨其可能的作用机制。方法:依托中药系统药理数据库和分析平台(TCMSP)筛选出人参有效成分及靶点。利用疗效药靶数据库(TTD)、比较毒物遗传学数据库(CTD)、基因名片数据库(Gene Cards)筛选出NSCLC靶点。利用Cytoscape软件构建人参-靶点蛋白相互作用(PPI)网络和NSCLC-靶点PPI网络,取两个PPI 网络交集筛选得到核心靶点并进行分析。利用分子对接技术验证预测结果。结果:共筛选出22个活性成分、118个化合物靶点和79个NSCLC靶点,进一步分析后得到26个核心靶点,其中涉及表皮生长因子受体(EGFR)、鼠双微体(MDM)2/4等信号通路。模拟对接表明,人参成分与EGFR、MDM2/4等靶点具有较强亲和力。结论:人参治疗NSCLC的作用机制可能主要与EGFR和MDM2/4等信号通路有关。
Abstract:
Objective:To predict the potential targets of ginseng in the treatment of non-small cell lung cancer(NSCLC)based on network pharmacology and molecular docking technology and explore its possible mechanism of action.Methods:Relying on TCMSP,the components and targets of ginseng were screened out.The NSCLC targets were screened out by using TTD,CTD and Gene Cards.Cytoscape software was used to construct a ginseng-target PPI network and NSCLC-target PPI network,and the intersection of the two PPI networks was selected to obtain the core target and analyzed.Molecular docking technology was used to verify the prediction results.Results:22 active components,118 compound targets and 79 NSCLC targets were screened out.After further analysis,26 core targets were obtained,which involved signaling pathway such as EGFR,MDM2/4.Simulation docking showed that ginseng components had strong affinity with targets such as EGFR and MDM2/4.Conclusion:The mechanism of ginseng in the treatment of NSCLC may be mainly related to EGFR and MDM2/4 signaling pathways.

参考文献/References:

[1] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Cli,2018,68(6):394-424.
[2] Siegel RL,Miller KD,Jemal A.Cancer statistics,2019[J].CA Cancer J Cli,2019,69(1):7-34.
[3] Zappa C,Mousa SA.Non-small cell lung cancer:Current treatment and future advances[J].Translational Lung Cancer Research,2016,5(3):288.
[4] 张孝钦,喻 飒,邬盛昌.人参多糖对晚期肺癌化疗疗效及MDSCs、Treg细胞、免疫因子水平的影响[J].中华全科医学,2019,17(8):1308-1311.
[5] 高笑一,鲍建才,管丽娜,等.人参多糖药理活性国内研究新进展[J].人参研究,2018,30(5):41-44.
[6] 杨晓瑞,王 江,潘 琼,等.奥希替尼联合人参皂苷Rg3对非小细胞肺癌H1975细胞增殖和凋亡的影响[J].新乡医学院学报,2020,37(11):1007-1012,1017.
[7] Wei TZ,Wang H,Wu XQ,et al.In silico screening of potential spike glycoprotein inhibitors of SARS-CoV-2 with drug repurposing strategy[J].Chinese Journal of Integrative Medicine,2020,26(9):663-669.
[8] 刘 驰,袁 宇,赵文婷,等.利用网络药理学方法预测金丝桃苷治疗动脉粥样硬化的作用靶点及作用机制[J].中国现代中药,2018,20(6):684-701.
[9] Ahmed MF,Santali EY,El-Haggar R.Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design,synthesis,molecular docking studies,and anticancer evaluation[J].J Enzyme Inhib Med Chem,2021,36(1):307-318.
[10] 王翠翠,耿利民.血清癌胚抗原对表皮生长因子受体基因突变非小细胞肺癌分子靶向治疗疗效的预测价值[J].陕西医学杂志,2020,49(7):834-837.
[11] Gevaert O,Echegaray S,Khuong A,et al.Predictive radiogenomics modeling of EGFR mutation status in lung cancer[J].Scientific Reports,2017,7(1):1-8.
[12] Chen Y,Li H,Zhang W,et al.Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway[J].Toxicol Appl Pharmacol,2020,387:114848.
[13] 夏 青,周茜宁,张 琳,等.表皮生长因子受体与非小细胞肺癌关系的研究进展[J].医学综述,2021,27(4):717-721.
[14] Park SJ,Kang HJ,Jun HJ,et al.Multi-center,randomized,double-blind,placebo-controlled,exploratory study to evaluate the efficacy and safety of HAD-B1 for dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy:Study protocol clinical trial[J].Medicine,2020,99(4):e18735.
[15] Liu J,Zhong Y,Peng S,et al.Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer:A meta-analysis[J].Onco Targets and Therapy,2018,11:8623-8632.
[16] Bai R,Chen N,Cui J.Study progression on non-small cell lung cancer with EGFR mutation treated by immune checkpoint inhibitors[J].Chinese Journal of Lung Cancer,2018,21(8):641-648.
[17] Kim TJ,Hong SA,Kim O,et al.Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer[J].Oncotarget,2017,8(64):107630-107639.
[18] 崔 凯,王武平,孙 盈,等.非小细胞肺癌中Twist通过TGF-β/Smad3信号通路促进EMT的发生[J].陕西医学杂志,2016,45(11):1462-1465.
[19] Arena G,Cissé MY,Pyrdziak S,et al.Mitochondrial MDM2 regulates respiratory complex Ⅰ activity independently of p53[J].Molecular Cell,2018,69(4):594-609.
[20] Xing Y,Liu Y,Liu T,et al.TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway[J].Cell Commun Signal,2018,16(1):43.
[21] Hai J,Sakashita S,Allo G,et al.Inhibiting MDM2-p53 interaction suppresses tumor growth in patient-derived non-small cell lung cancer xenograft models[J].J Thorac Oncol,2015,10(8):1172-1180.

相似文献/References:

[1]才 昊,韩 亮,李晓飞.LncRNA XIST通过调控miR-186-5p促进非小细胞肺癌的增殖和侵袭实验研究*[J].陕西医学杂志,2020,49(7):781.[doi:DOI:10.3969/j.issn.10007377.2020.07.004]
　CAI Hao,HAN Liang,LI Xiaofei..LncRNA XIST promotes proliferation and invasion of non-small cell lung cancer by regulating miR-186-5p[J].,2020,49(6):781.[doi:DOI:10.3969/j.issn.10007377.2020.07.004]
[2]王冠杰,王 鹏△.培美曲塞联合顺铂治疗非小细胞肺癌疗效及对患者细胞角质抗原21-1、磷酸化细胞外信号调节激酶水平的影响研究*[J].陕西医学杂志,2020,49(7):804.[doi:DOI:10.3969/j.issn.10007377.2020.07.009]
　WANG Guanjie,WANG Peng..Therapeutic effect of pemetrexed combined with cisplatin in treatment of non-small cell lung cancer and its influence on CYFRA21-1 and p-ERK levels[J].,2020,49(6):804.[doi:DOI:10.3969/j.issn.10007377.2020.07.009]
[3]王翠翠,耿利民△.血清癌胚抗原对表皮生长因子受体基因突变非小细胞肺癌分子靶向治疗疗效的预测价值[J].陕西医学杂志,2020,49(7):834.[doi:DOI:10.3969/j.issn.10007377.2020.07.018]
　WANG Cuicui,GENG Limin..Predictive value of serum CEA in molecular targeted therapy of non-small cell lung cancer patients with EGFR gene mutation[J].,2020,49(6):834.[doi:DOI:10.3969/j.issn.10007377.2020.07.018]
[4]信 波,张开亮△,宋晓鹏,等.雌激素受体β拮抗剂对非小细胞肺癌A549细胞增殖、迁移及侵袭能力的影响*[J].陕西医学杂志,2020,49(10):1223.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.006]
　XIN Bo,ZHANG Kailiang,SONG Xiaopeng,et al.Effect of estrogen receptor β antagonist PHTPP on proliferation,migration and invasion of non-small cell lung cancer A549 cells[J].,2020,49(6):1223.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.006]
[5]惠 盼,谯钰琪,董济民,等.葡萄糖调节蛋白78表达与非小细胞肺癌临床病理特征相关性Meta分析[J].陕西医学杂志,2023,52(4):481.[doi:DOI:10.3969/j.issn.1000-7377.2023.04.027]
[6]解宝泉,姚仲欣.非小细胞肺癌并发肺栓塞患者微小核糖核酸-1233、血清碱性成纤维细胞生长因子、血细胞参数变化及与患者预后关系[J].陕西医学杂志,2023,52(10):1349.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.014]
　XIE Baoquan,YAO Zhongxin.Changes of miR-1233,bFGF and blood cell parameters in NSCLC patients with pulmonary embolism and their relationship with prognosis[J].,2023,52(6):1349.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.014]
[7]王莉云,王会丽,盛国芳,等.奥西替尼二线治疗EGFR T790M突变非小细胞肺癌脑转移临床研究[J].陕西医学杂志,2024,(7):962.[doi:DOI:10.3969/j.issn.1000-7377.2024.07.021]

备注/Memo

备注/Memo:
基金项目:辽宁省重点研发计划项目(2019JH2/10300046)
更新日期/Last Update: 2021-06-07